Low-dose 123I-metaiodobenzylguanidine diagnostic scan is inferior to 131I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma

Kayano, Daiki; Taki, Junichi; Fukuoka, Masayoshi; Wakabayashi, Hiroshi; Inaki, Anri; Nakamura, Ayane; Kinuya, Seigo

doi:10.1097/mnm.0b013e32834a4445

Cited by 8 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Less common in small animal scanners because of this, in humans, it has "theranostic" possibilities for simultaneous therapeutic and diagnostic imaging applications (1,53).…”

Section: Radiolabeling With Iodinementioning

confidence: 99%

Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging

Williams¹

2012

AAPS J

View full text Add to dashboard Cite

Abstract. Molecular imaging techniques for protein therapeutics rely on reporter labels, especially radionuclides or sometimes near-infrared fluorescent moieties, which must be introduced with minimal perturbation of the protein's function in vivo and are detected non-invasively during whole-body imaging. PET is the most sensitive whole-body imaging technique available, making it possible to perform biodistribution studies in humans with as little as 1 mg of injected antibody carrying 1 mCi (37 MBq) of zirconium-89 radiolabel. Different labeling chemistries facilitate a variety of optical and radionuclide methods that offer complementary information from microscopy and autoradiography and offer some trade-offs in whole-body imaging between cost and logistic difficulty and image quality and sensitivity (how much protein needs to be injected). Interpretation of tissue uptake requires consideration of label that has been catabolized and possibly residualized. Image contrast depends as much on background signal as it does on tissue uptake, and so the choice of injected dose and scan timing guides the selection of a suitable label and helps to optimize image quality. Although only recently developed, zirconium-89 PET techniques allow for the most quantitative tomographic imaging at millimeter resolution in small animals and they translate very well into clinical use as exemplified by studies of radiolabeled antibodies, including trastuzumab in breast cancer patients, in The Netherlands.

show abstract

“…Less common in small animal scanners because of this, in humans, it has "theranostic" possibilities for simultaneous therapeutic and diagnostic imaging applications (1,53).…”

Section: Radiolabeling With Iodinementioning

confidence: 99%

Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging

Williams¹

2012

AAPS J

View full text Add to dashboard Cite

show abstract

“…This personalized method demonstrated high response rates and manageable toxicity. Comparatively, low-dose diagnostic scans with 123 I-MIBG were found to be less effective than post-treatment scans with 131 I-MIBG in detecting malignant pheochromocytoma and paraganglioma, underscoring the importance of scan timing and dose in diagnostic accuracy 85 .…”

Section: Net-targeted Therapy With Beta and Alpha Emittersmentioning

confidence: 95%

Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine

Higuchi,

Chen,

Werner

2024

Theranostics

View full text Add to dashboard Cite

In the evolving landscape of precision medicine, NET-targeted radiopharmaceuticals are emerging as pivotal tools for the diagnosis and treatment of a range of conditions, from heart failure and neurodegenerative disorders to neuroendocrine cancers. This review evaluates the advancements offered by 18 F-labeled PET tracers and 211 At alpha-particle therapy, juxtaposed with current 123 I-MIBG SPECT and 131 I-MIBG therapies. The enhanced spatial resolution and capability for quantitative analysis render 18 F-labeled PET tracers potential candidates for improved detection and management of diseases. Alpha-particle therapy with 211 At may offer increased specificity and tumoricidal efficacy, pointing towards a shift in therapeutic protocols. While preliminary data is promising, these innovative approaches require thorough validation against current modalities. Ongoing clinical trials are pivotal to confirm the expected clinical benefits and to address safety concerns. This review underscores the need for rigorous research to verify the clinical utility of NET-targeted radiopharmaceuticals, which may redefine precision medicine paradigms and significantly impact patient care.

show abstract

“…Post-therapy 131 I-mIBG scintigraphy may detect more lesions compared with diagnostic 123 I-mIBG scintigraphy in children with neuroblastoma [ 9 ]. This may be due to different kinetics, the presence of a higher amount of carriers, and delayed scanning time [ 10 , 11 , 12 ]. Patients with sustained CR had residual avid lesions in post-therapy 131 I-mIBG scan as demonstrated in the 123 I-mIBG scintigraphy.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

123I-meta-iodobenzylguanidine (123I-mIBG) scintigraphy is used for evaluating disease extent in children with neuroblastoma. 131I-mIBG therapy has been used for evaluation in children with high-risk neuroblastoma, and post-therapy 131I-mIBG scintigraphy may detect more lesions compared with diagnostic 123I-mIBG scintigraphy. However, no studies have yet revealed the detection rate of hidden mIBG-avid lesions on post-therapy 131I-mIBG whole-body scan (WBS) and SPECT images in neuroblastoma children without mIBG-avid lesions as demonstrated by diagnostic 123I-mIBG scintigraphy. We retrospectively examined the diagnostic utility of post-therapy 131I-mIBG scintigraphy in children who received 131I-mIBG as consolidation therapy. Nineteen children with complete response to primary therapy were examined. Post-therapy 131I-mIBG scintigraphy was performed four days after injection. The post-therapy 131I-mIBG scintigraphy, 4 children exhibited abnormal uptake on the WBS. Post-therapy 131I-mIBG SPECT/CT provided additional information in 2 cases. In total, 6 children exhibited abnormal uptake. The site of abnormal accumulation was on the recurrence site in one case, operation sites in five cases, and bone metastasis in one case. Post-therapy 131I-mIBG scintigraphy could detect residual disease that was not recognized using diagnostic 123I-mIBG scintigraphy in 32% of children with high-risk neuroblastoma and ganglioneuroblastoma. The diagnostic use of post-therapy 131I-mIBG scintigraphy can provide valuable information for detecting residual disease.

show abstract

Low-dose 123I-metaiodobenzylguanidine diagnostic scan is inferior to 131I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma

Cited by 8 publications

References 27 publications

Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging

Tissue Distribution Studies of Protein Therapeutics Using Molecular Probes: Molecular Imaging

Navigating new horizons: Prospects of NET-targeted radiopharmaceuticals in precision medicine

Diagnostic Use of Post-therapy 131I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma

Contact Info

Product

Resources

About